ChemDiv discovery platform tapped to advance R&D pipeline into preclinical studies

08-Nov-2017 - Last updated on 08-Nov-2017 at 17:13 GMT

(Image: Gety/Kichigin)

The Tri-Institutional Therapeutics Discovery Institute, Inc. will use ChemDiv's proprietary discovery chemistry platform to advance its research and development (R&D) pipeline.

The Tri-Institutional community (Tri-I TDI) includes the Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine.

Tri-I TDi also announced a partnership with Charles River in October 2016, which focuses on the early stages of compound and biologic agent development.

Through its collaboration with ChemDiv, a California-based contract research organization (CRO), Tri-I TDI will use its proprietary technology to advance the development of therapies across multiple therapeutic areas.

Rom Demuth, SVP and general manager at ChemDiv told us the company will be providing diverse and focused discovery chemistry, hit expansion libraries, rapid-turnaround medicinal chemistry, and SAR.

"The collaboration is opened-ended," he added.

ChemDiv’s discovery platform is also used by Janssen Research and Development. The hit identification collaboration, announced in February 2017, is one of five agreements the CRO has with pharma partners, the first of which was initiated in 2010.